CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for chlorpheniramine polistirex; hydrocodone polistirex and what is the scope of freedom to operate?
Chlorpheniramine polistirex; hydrocodone polistirex
is the generic ingredient in four branded drugs marketed by Ecr Pharma, Tris Pharma Inc, Neos Theraps Inc, and Ucb Inc, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.Three suppliers are listed for this compound.
Summary for CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 4 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 3 |
| Clinical Trials: | 2 |
| DailyMed Link: | CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX at DailyMed |
Recent Clinical Trials for CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mallinckrodt | Phase 1 |
See all CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX clinical trials
Pharmacology for CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX
| Drug Class | Histamine-1 Receptor Antagonist Opioid Agonist |
| Mechanism of Action | Histamine H1 Receptor Antagonists Opioid Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX
Paragraph IV (Patent) Challenges for CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| TUSSIONEX PENNKINETIC | Extended-release Capsules | chlorpheniramine polistirex; hydrocodone polistirex | 8 mg/10 mg and 4 mg/5 mg | 019111 | 1 | 2004-09-10 |
US Patents and Regulatory Information for CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neos Theraps Inc | HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX | chlorpheniramine polistirex; hydrocodone polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 091671-001 | Jun 29, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ecr Pharma | TUSSICAPS | chlorpheniramine polistirex; hydrocodone polistirex | CAPSULE, EXTENDED RELEASE;ORAL | 077273-001 | Sep 24, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Tris Pharma Inc | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | chlorpheniramine polistirex; hydrocodone polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 091632-001 | Oct 1, 2010 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ecr Pharma | TUSSICAPS | chlorpheniramine polistirex; hydrocodone polistirex | CAPSULE, EXTENDED RELEASE;ORAL | 077273-002 | Sep 24, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ucb Inc | TUSSIONEX PENNKINETIC | chlorpheniramine polistirex; hydrocodone polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 019111-001 | Dec 31, 1987 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ucb Inc | TUSSIONEX PENNKINETIC | chlorpheniramine polistirex; hydrocodone polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 019111-001 | Dec 31, 1987 | ⤷ Sign Up | ⤷ Sign Up |
| Ucb Inc | TUSSIONEX PENNKINETIC | chlorpheniramine polistirex; hydrocodone polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 019111-001 | Dec 31, 1987 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
